Shenzhen Hepalink Acquires U.S. API Manufacturer Scientific Protein Laboratories
This article was originally published in PharmAsia News
Executive Summary
Shenzhen Hepalink Pharmaceutical acquired 100% of the equity interest of Scientific Protein Laboratories (SLP), a U.S. leading manufacturer of heparin active pharmaceutical ingredients (APIs) for $2.075 billion Jan. 13.
You may also be interested in...
Hepalink-Backed HighTide Bets On NASH For Global Markets
Emerging Company Profile: Fatty liver disease has been a hot development area that keeps getting more attention, and one Chinese startup backed by the world’s largest heparin manufacturer is looking to launch a new therapy globally.
Biden Administration Is Setting An Example For Safe AI Use In Federal Organizations
A new memorandum by the Director of the Office of Management and Budget initiated a government-wide policy that will appoint AI officers to all agencies to address risks for AI use and serve as an example for greater AI adoption.
US FDA Drugs Center Ready To Break Down Silos On Regulatory Innovation
CDER Director Cavazzoni is promising to increase coordination and collaboration to accelerate broader adoption of innovative clinical trial designs and other approaches to speed drug development. A new "Quantitative Medicine Center of Excellence" illustrates the approach.